Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study

被引：12

作者：

Piccaluga, Pier Paolo ^{[1
]}

Malagola, Michele ^{[2
]}

Rondoni, Michela ^{[1
]}

Arpinati, Mario ^{[1
]}

Paolini, Stefania ^{[1
]}

Candoni, Anna ^{[1
]}

Fanin, Renato ^{[3
]}

Messa, Emanuela ^{[4
]}

Pirrotta, Maria Teresa ^{[5
]}

Lauria, Francesco ^{[5
]}

Visani, Giuseppe ^{[6
]}

Alberti, Daniele

Rancati, Francesca

Vinaccia, Vincenza ^{[7
]}

Russo, Domenico

Saglio, Giuseppe ^{[4
]}

Baccarani, Michele ^{[1
]}

Martinelli, Giovanni ^{[1
]}

机构：

[1] Univ Bologna, S Orsola Malpighi Hosp, Inst Hematol & Med Oncol L & A Seragnoli, Via Massarenti 9, I-40138 Bologna, Italy

[2] Univ Brescia, Dept Hematol, Brescia, Italy

[3] Univ Udine, Dept Hematol, Udine, Italy

[4] Univ Torino, Dept Hematol, Orbassano, Turin, Italy

[5] Univ Siena, Dept Hematol, Siena, Italy

[6] Dept Hematol, Pesaro, Italy

[7] Novartis Pharmaceut, Origgio, Italy

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 12期

关键词：

imatinib mesylate; acute myeloid leukemia; c-KIT; PDGFRB; targeted therapy;

D O I：

10.3324/haematol.11345

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.

引用

页码：1721 / 1722

页数：2

共 50 条

[21] Structure-based drug design of C-kit inhibitors for use in the treatment of acute myeloid leukemia.
Maxwell, David S.
Pal, Ashutosh
Peng, Zhenghong
Shavrin, Alexandr
Faderl, Stefan
Harris, David
Van, Quin
Liu, Zhiming
Verstovsek, Srdan
Manshouri, Taghi
Ferrajoli, Alessandra
Kantarjian, Hagop M.
Estrov, Zeev
Bornmann, William G.
BLOOD, 2006, 108 (11) : 540A - 540A
[22] Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia.
Ravandi, F.
Faderl, S.
Cortes, J. E.
Garcia-Manero, G.
Jabbour, E.
Boone, P. A.
Kadia, T. M.
Borthakur, G.
Wierda, W. G.
Chiao, J. H.
Kantarjian, H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[23] Molecular response to imatinib in late chronic phase chronic myeloid leukemia. results of a phase II study by the Italian cooperative study group on chronic myeloid leukemia (ICSG on CML).
Rosti, G
Bassi, S
Elena, T
Testoni, N
Amabile, M
Martinelli, G
Giannini, B
De Vivo, A
Luatti, S
Bonifazi, F
Izzo, B
Salvatore, F
Gottardi, E
Cambrin, GR
Cilloni, D
Tiribelli, M
Pane, F
Russo, D
Saglio, G
Michele, B
BLOOD, 2003, 102 (11) : 907A - 907A
[24] High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
Kantarjian, H
Talpaz, M
O'Brien, SS
Garcia-Manero, G
Verstovsek, S
Giles, F
Rios, MB
Shan, JQ
Letvak, L
Thomas, D
Faderl, S
Ferrajoli, A
Cortes, J
BLOOD, 2004, 103 (08) : 2873 - 2878
[25] Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan
Tadashi Nagai
Jin Takeuchi
Nobuaki Dobashi
Yuzuru Kanakura
Shuichi Taniguchi
Koji Ezaki
Chiaki Nakaseko
Akira Hiraoka
Masaya Okada
Yasushi Miyazaki
Toshiko Motoji
Masaaki Higashihara
Norifumi Tsukamoto
Hitoshi Kiyoi
Shinji Nakao
Katsuji Shinagawa
Ryuzo Ohno
Tomoki Naoe
Kazunori Ohnishi
Noriko Usui
International Journal of Hematology, 2010, 92 : 111 - 117
[26] Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan
Nagai, Tadashi
Takeuchi, Jin
Dobashi, Nobuaki
Kanakura, Yuzuru
Taniguchi, Shuichi
Ezaki, Koji
Nakaseko, Chiaki
Hiraoka, Akira
Okada, Masaya
Miyazaki, Yasushi
Motoji, Toshiko
Higashihara, Masaaki
Tsukamoto, Norifumi
Kiyoi, Hitoshi
Nakao, Shinji
Shinagawa, Katsuji
Ohno, Ryuzo
Naoe, Tomoki
Ohnishi, Kazunori
Usui, Noriko
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (01) : 111 - 117
[27] A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response
J M Brandwein
D W Hedley
S Chow
A D Schimmer
K W L Yee
A C Schuh
V Gupta
W Xu
S Kamel-Reid
M D Minden
Leukemia, 2011, 25 : 945 - 952
[28] A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response
Brandwein, J. M.
Hedley, D. W.
Chow, S.
Schimmer, A. D.
Yee, K. W. L.
Schuh, A. C.
Gupta, V.
Xu, W.
Kamel-Reid, S.
Minden, M. D.
LEUKEMIA, 2011, 25 (06) : 945 - 952
[29] A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β
Clinton Yam
Rashmi K. Murthy
Gaiane M. Rauch
James L. Murray
Ronald S. Walters
Vicente Valero
Abenaa M. Brewster
Robert C. Bast
Daniel J. Booser
Sharon H. Giordano
Francisco J. Esteva
Wei Yang
Gabriel N. Hortobagyi
Stacy L. Moulder
Banu Arun
Investigational New Drugs, 2018, 36 : 1103 - 1109
[30] A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-
Yam, Clinton
Murthy, Rashmi K.
Rauch, Gaiane M.
Murray, James L.
Walters, Ronald S.
Valero, Vicente
Brewster, Abenaa M.
Bast, Robert C., Jr.
Booser, Daniel J.
Giordano, Sharon H.
Esteva, Francisco J.
Yang, Wei
Hortobagyi, Gabriel N.
Moulder, Stacy L.
Arun, Banu
INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1103 - 1109

← 1 2 3 4 5 →